Search Results

Nearly a third of employed and almost half of unemployed BioSpace survey respondents are seriously considering leaving the U.S. to find biotech and pharma jobs. Concerns about how the political climate is affecting biopharma are a key driver for many.

The 2025 BIO International Convention (BIO2025), the world’s largest annual biotech event, will take place from June 16 to 19 (U.S. time) at the Boston Convention & Exhibition Center. This year, Taipei City Government is partnering with six Taipei-based biotech companies, including PanCAD.ai Co., Ltd., Instant NanoBiosensors Co., Ltd., Bened Biomedical Co., Ltd., Cancer Free Biotech Ltd., Xantho Biotechnology Co., Ltd., and Energenesis Biomedical Co., Ltd., to showcase their innovations at the Taiwan Pavilion (Booth #1645) in the Taipei Exhibition Area.

BioSpace’s NextGen companies are rising in one of the most confounding biotech markets ever experienced. Executives sounded off on how to keep your head above water during our webinar, Are We There Yet?

Jefferies has predicted more small tuck-in deals to come, as biotechs struggle to access capital despite key clinical milestones on the horizon.

Advent International, one of the largest and most experienced global private equity investors, and Warburg Pincus, a leading global growth investor, announced the completion of their previously announced acquisition of Baxter International Inc.’s BioPharma Solutions business.

From ADCs and radiopharmaceuticals to cell and gene therapies, eager young startups are betting on advances in biopharma’s most competitive therapeutic spaces—and attracting dollars from Big Pharma.

Big Pharma executives have not been shy about their desire for deals, but companies have been battling macro headwinds alongside Trump’s policies on drug pricing and tariff threats.

In May, Revolution Medicines projected its cash and equivalents of $2.1 billion would last into the second half of 2027. With new funding from Royalty Pharma, the biotech has withdrawn that runway end date.